Literature DB >> 21378318

miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer.

Aida Gordanpour1, Aleksandra Stanimirovic, Robert K Nam, Carlos S Moreno, Christopher Sherman, Linda Sugar, Arun Seth.   

Abstract

Expression profiling studies using microarrays and other methods have shown that microRNAs (miRNAs) are dysregulated in a wide variety of human cancers. The up-regulation of miR-221 has been reported in carcinomas of the pancreas, breast, and papillary thyroid, as well as in glioblastoma and chronic lymphocytic leukaemia. In prostate cancer, however, down-regulation of miR-221 has been repeatedly confirmed in miRNA expression studies. Also unique to prostate cancer, and found in more than 50% of patients, is the aberrant expression of a known oncogene, the TMPRSS2:ERG fusion. To date, there has been no published study describing miRNA associations in prostate tumours that overexpress the ERG oncogene from the TMPRSS2:ERG fusion transcript. Herein we report that in a large and diverse cohort of prostate carcinoma samples, miR-221 is down-regulated in patients with tumours bearing TMPRSS2:ERG fusion transcripts, thus providing a link between miRNA and gene fusion expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378318      PMCID: PMC3281770     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  40 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

2.  HPC2 variants and screen-detected prostate cancer.

Authors:  D Vesprini; R K Nam; J Trachtenberg; M A Jewett; S V Tavtigian; M Emami; M Ho; A Toi; S A Narod
Journal:  Am J Hum Genet       Date:  2001-03-14       Impact factor: 11.025

3.  Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.

Authors:  Robert K Nam; John Trachtenberg; Michael A S Jewett; Ants Toi; Andrew Evans; Marjan Emami; Steven A Narod; Michael Pollak
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-05       Impact factor: 4.254

4.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  Extensive modulation of a set of microRNAs in primary glioblastoma.

Authors:  S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

6.  MicroRNA gene expression deregulation in human breast cancer.

Authors:  Marilena V Iorio; Manuela Ferracin; Chang-Gong Liu; Angelo Veronese; Riccardo Spizzo; Silvia Sabbioni; Eros Magri; Massimo Pedriali; Muller Fabbri; Manuela Campiglio; Sylvie Ménard; Juan P Palazzo; Anne Rosenberg; Piero Musiani; Stefano Volinia; Italo Nenci; George A Calin; Patrizia Querzoli; Massimo Negrini; Carlo M Croce
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

7.  MicroRNAs modulate hematopoietic lineage differentiation.

Authors:  Chang-Zheng Chen; Ling Li; Harvey F Lodish; David P Bartel
Journal:  Science       Date:  2003-12-04       Impact factor: 47.728

8.  The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism.

Authors:  Peizhang Xu; Stephanie Y Vernooy; Ming Guo; Bruce A Hay
Journal:  Curr Biol       Date:  2003-04-29       Impact factor: 10.834

9.  Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy.

Authors:  Robert K Nam; Michael A S Jewett; Murray D Krahn; Michael A Robinette; John Tsihlias; Ants Toi; Minnie Ho; Andrew Evans; Joan Sweet; John Trachtenberg
Journal:  Can J Urol       Date:  2003-06       Impact factor: 1.344

10.  Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.

Authors:  Martin Spahn; Susanne Kneitz; Claus-Jürgen Scholz; Nico Stenger; Thomas Rüdiger; Philipp Ströbel; Hubertus Riedmiller; Burkhard Kneitz
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

View more
  26 in total

1.  MicroRNA detection in prostate tumors by quantitative real-time PCR (qPCR).

Authors:  Aida Gordanpour; Robert K Nam; Linda Sugar; Stephanie Bacopulos; Arun Seth
Journal:  J Vis Exp       Date:  2012-05-16       Impact factor: 1.355

2.  miR-221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BMF.

Authors:  Xinping Xie; Yuxiu Huang; Lihong Chen; Jinhua Wang
Journal:  Oncol Lett       Date:  2018-09-18       Impact factor: 2.967

3.  microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.

Authors:  Ashraf Bakkar; Mohammed Alshalalfa; Lars F Petersen; Hatem Abou-Ouf; Amal Al-Mami; Samar A Hegazy; Felix Feng; Reda Alhajj; Krikor Bijian; Moulay A Alaoui-Jamali; Tarek A Bismar
Journal:  Mol Biol Rep       Date:  2016-02-23       Impact factor: 2.316

4.  Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.

Authors:  Qizhi Zheng; Sarah B Peskoe; Judit Ribas; Fatema Rafiqi; Tarana Kudrolli; Alan K Meeker; Angelo M De Marzo; Elizabeth A Platz; Shawn E Lupold
Journal:  Prostate       Date:  2014-09-22       Impact factor: 4.104

Review 5.  ERG expression in prostate cancer: biological relevance and clinical implication.

Authors:  Hatem Abou-Ouf; Liena Zhao; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-28       Impact factor: 4.553

Review 6.  MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans.

Authors:  J Jones; W Grizzle; H Wang; C Yates
Journal:  Biotech Histochem       Date:  2013-08-01       Impact factor: 1.718

Review 7.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 8.  miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells.

Authors:  Sundas Fayyaz; Ammad Ahmad Farooqi
Journal:  Immunogenetics       Date:  2013-04-05       Impact factor: 2.846

9.  Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA.

Authors:  Shaan Sarkar; Hala Dubaybo; Shadan Ali; Priscila Goncalves; Sri Lakshmi Kollepara; Seema Sethi; Philip A Philip; Yiwei Li
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

Review 10.  miRNAs as biomarkers in prostate cancer.

Authors:  Irene Casanova-Salas; José Rubio-Briones; Antonio Fernández-Serra; Jose Antonio López-Guerrero
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.